BioCurex, Inc.(fka BOCX)

[onthepath]

From: "OTCJournal" <[e-mail]>
To: <[e-mail]>
Subject: Time to Tap the Market's Other Hot Spot
Date: Wednesday, September 09, 2009 6:00 PM

If you are reading this message in plaintext or if you have an AOL address you must click on this link: <A HREF="http://www.otcjournal.com/archive/listserv/20090909-1.html" target="_blank">http://www.otcjournal.com/archive/listserv/20090909-1.html</A> and wait for a web page to automatically open up to properly read this newsletter.





September 9, 2008 Volume X, Issue 82


Home Page : www.otcjournal.com
Email Questions or Comments To: [e-mail]

To OTC Journal Members:

For the last several weeks I've been focused on Chinese stocks as a
way to get the most bang for our trading buck. And, it's worked out
pretty well.... NF Energy Saving Corp. (NFEC) is up about 165% from
our entry, Universal Travel (UTA) more than doubled after our June
entry, and our China ETF (FXI) trade - which goes all the way back
to December of last year - is up about 70%.

While I love the overall results, I don't want ignore a few other
opportunistic hot spots we could be (and should be) tapping into
right now. To that end, a new trading idea is immediately below. I
want to add one more layer of perspective before we get to it
though....

How would you like to own part of a $4 million company that could
be a serious contender in a $1 billion market? Moreover, how would
you like to step into a position at only 7 cents per share? Oh, did
I mention the market has renewed its love affair with this
industry?

I can't recall the last time I saw a penny stock with this much
upside potential trading at these stunningly low levels. I think
the market's going to rediscover this one again real soon though,
pushing the valuation up in a hurry.

The Future of Cancer Detection

Let's not mince words here - many of the standard cancer detection
tests are just bad. Either they're expensive, slow, or inaccurate
(or some combination of all three). BioCurex Inc. (OTCBB: BOCX) has
developed a technology that can potentially address all three
problems with the cancer screening process.

The opportunity BOCX investors could tap through the
company's diagnostic equipment isn't a small one either.
The cancer detection/screening market is worth about $1 billion
each year. Even a small sliver of that pie could reap relatively
huge rewards for BioCurex owners; the company's market cap is only
about $4 million, so a small investment gives you a large stake in
the company's success.

The continued development of the screening technology is the key
here though, so let's take a look...

At the heart of everything BioCurex is, you'll find RECAF
(tm). All cancerous cells cause the creation of the RECAF
molecule, while healthy cells don't cause the creation of this same
molecule. Therefore, a positive RECAF test means cancer has been
detected.

Simple so far? We'd agree, but there are three things that could
make RECAF-based diagnostics more attractive and lucrative than the
other current forms of testing.... accuracy, speed, and cost.

Accuracy

Stunningly, many other cancer tests may as well be coin tosses.
Take prostate cancer for instance. Of all the 'positive' results
yielded for a common PSA test, only 1/3 of them are actually
accurate. The other 2/3 are false 'positives'. It gets worse
though, because some of the 'negatives' for this test should
actually be 'positive', meaning the patient has prostate cancer and
may not even know it. All told, that PSA test is only about 40%
accurate, which leads one to wonder if it's doing more harm than
good.

When using the RECAF test to detect prostate cancer, the overall
accuracy is cranked up to close to 90%.

And just to clarify, RECAF can screen for all cancers, since it's
searching for that one certain molecule that only exists if cancer
is present. Other tests in current use aim to indicate only one
particular form of cancer.

Speed

As with any lab work, sending blood/serum samples from a
doctor's office to a lab takes time, and manpower is
needed to generate the test's results. That's just the way it is...
or was, until BioCurex began to develop a rapid RECAF test -
something that could be performed during an office visit with
results being returned in a matter of minutes.

Since then, the device has been fully developed - and it works. The
nearby image is a picture of a utilized test. Even to the amateur
eye it's clear the rapid RECAF test can be highly accurate. While
the lab version of the test is still utilized where a lab
confirmation is preferred, the rapid test is a functional and fast
screening test... something oncologists really don't have access to
as of right now.

Cost

The cost to process most current cancer screening tests (materials,
lab work, shipping, and the doctor's time) can vary from $75 to
$800, depending on the test. If the expense isn't paid by the
insurance company, it's paid out of the patient's pocket.

Having constructed a few versions of the rapid RECAF test already,
BioCurex estimates their cancer diagnostic device will cost
somewhere between $10 and $20.

While the price difference clearly favors use of the rapid test,
there may be an even bigger, unrealized and unintended benefit to
the RECAF test - it may actually be performed in those cases where
the more expensive tests may not be approved by insurance
companies, or declined by patients who would otherwise pay for such
a test out of pocket.

Trading BOCX

The next steps for the company are to continue making progress
towards the commercialization of the RECAF screening test.
Nothing's been publicly confirmed yet, but in reviewing the
company's history and news, one has to believe BioCurex has been
lining up some deals and licensees.

With that being said, I've got two final points to make.

First, most of you know how biotech works - a huge portion of a
stock's gains come before the biotech company makes its first
cent.

Take Gilead Sciences (GILD) or Vertex Pharmaceuticals (VRTX) for
instance. Gilead wasn't even close to being profitable until the
fourth quarter of 2001, yet shares rallied from $1.00 to $7.00 over
the nine years before that swing to a profit. Vertex has only
posted six profitable quarters in the last 18 years (and none since
2003), yet VRTX shares are nearly 400% higher than they were 18
years ago.

That's not to say BioCurex is the next Gilead or Vertex. It might
be - I just don't know. All I'm saying is with biotech, if you're
not out in front, then you're automatically behind. That leads me
to my other message....

Second, I can't stress enough how well the timing of this trading
idea has lined up.

Like almost all stocks, BOCX suffered the bear market by
pulling back from its 2007 peak around 90 cents. The
tumble didn't stop until March of this year, as was also the case
with the rest of the market. Welcome to the club. Since then, BOCX
has been range-bound between 4 cents and 11 cents while the rest of
the biotech market has rallied.

But wait a second... how is it a good thing if BioCurex trails?

The longer a stock can move in a range, the stronger the breakout
is likely to be once it materializes. And, given the market's
euphoria over biotech lately, I firmly believe it's more a matter
of 'when' rather than 'if' for BioCurex.

I'd never deny that it was the swine flu craze and Dendreon's
(DNDN) cancer vaccine update earlier in the year that jump-started
the biotech frenzy, but make no mistake - the buzz has been
sustained based on these biotech companies' own merits. I think
BioCurex's day is coming soon too.

One of the supporting clues to the theory is today's somewhat
mundane news release (below) from BioCurex. A couple of new
directors were named to the board.

I'd be the first to say it's not a barn-burner as far as news goes,
but having observed the BioCurex PR machine for a few years now,
I'd also say this is likely to be the beginning of a string of
company news that grows in importance as each press release is
posted. See, the company has historically posted news in waves, and
kicks those campaigns off with a mere 'stir the pot' kind of
release like this one.

I don't know for sure what's coming next in terms of announcements,
but I'm certain I'd rather wade in now between the $0.04 to $0.11
range instead of trying to chase BOCX if the next news item
catapults the stock. RECAF is simply a great biotechnology that has
the potential to send the major diagnostic companies back-pedaling,
and investors can participate in that for only 7 cents a share.
BOCX is not likely to stay priced at these levels for long.

So, here's how I'd suggest playing it - any entry under $0.11 cents
is fine, though something under $0.09 cents would be ideal. I don't
think a decent entry will be a problem though. As for a SSL, let's
use the bottom of the established range... $0.04 cents. I don't
want to set a target level just yet, but stay tuned for it.


Press Release Source: BioCurex

BioCurex Appoints Two New Directors.

RICHMOND, British Columbia, September 9, 2009 - Wispering
Oaks International, Inc. -- d/b/a BioCurex (OTCBB: BOCX) --
today announced that it has appointed Dr. Denis Burger and
Dr. Jim Walsh to its Board of Directors.

Dr. Burger will also assume the position of Executive
Chairman of BioCurex. He is a Director of both Trinity
Biotech plc, a successful diagnostics company, and Lorus
Therapeutics, a cancer therapeutics company. Dr. Burger was
the past Chairman, Chief Executive Officer and a director
of AVI Biopharma Inc, a publicly held biotechnology
company. Dr. Burger is also a partner in Sovereign
Ventures, a healthcare consulting and funding firm based in
Portland, Oregon. He co-founded and acted as Chairman of
Epitope Inc. until 1990. In addition, Dr. Burger has held a
professorship in the Department of Microbiology and
Immunology and Surgery (Surgical Oncology) at the Oregon
Health Sciences University in Portland. Dr. Burger received
his MSc and PhD in Microbiology and Immunology from the
University of Arizona.

Dr. Burger stated: "From my 30 years of experience in the
field, I am acutely aware of the importance of the
relationship between early cancer diagnosis and successful
treatment. I look forward to the opportunity to assist
BioCurex in connection with its development efforts in the
field of cancer diagnostics."

Dr. Jim Walsh is appointed as a non-executive Director. He
has 20 years general management experience in the
healthcare industry with particular experience in
diagnostics. He is a Director of Trinity Biotech Plc,
(NASDAQ: TRIB) and is also a Director of PuriCore Plc.
(LSE: PURI), a US-based healthcare company. He is currently
CEO of Biosensia Ltd., a point of care diagnostics company,
and interim CEO of Stokes Bio Ltd., a company specializing
in the area of molecular diagnostics. He is an investment
advisor to Bank of Ireland Kernel Capital Partners.
Previously Dr. Walsh was Managing Director of Cambridge
Diagnostics Ltd., a wholly owned subsidiary of Inverness
Medical Innovations Inc. Before joining CDL he worked with
Fleming GmbH as R&D Manager. Born in Ireland, Dr Walsh is a
graduate of the National University of Ireland and holds a
Doctorate in Inorganic Chemistry and Post Doctorate
qualifications in Immunochemistry.

Dr. Ricardo Moro, chief executive officer of BioCurex,
stated: "I am very proud of the interest BioCurex has
attracted from two executives of this caliber. Dr. Burger
and Dr. Walsh bring decades of broad experience in the
biotech industry. I look forward to working with them."

About BioCurex:

BioCurex is a biotechnology company that is developing
products based on patented/proprietary technology in the
areas of cancer diagnosis, imaging and therapy. The
technology identifies a cancer marker known as RECAFtm,
which is found on malignant cells from a variety of cancer
types but is absent in most normal or benign cells.

Note:

The Company has not authorized the release of this
information in any form that contravenes the Communication
Act and will not be responsible for unsolicited massive
distribution of this material by e-mail or facsimile by
unauthorized parties. Statements in this press release,
which are not historical facts, are "forward-looking
statements'' within the meaning given to that term in the
Private Securities Litigation Reform Act of 1995. The
Company intends that such forward-looking statements be
subject to the safe harbors created thereby. Since these
statements involve risks and uncertainties and are subject
to change at any time, the Company's actual results could
differ materially from expected results.

Contact:
Ricardo Moro
BioCurex
Tel: [phone]

--------------------------------------------------------------------
Refer A Friend

If you find the OTC Journal informative and profitable, please
forward our newsletter alert service to like-minded friends and
associates who share similar market interests.
--------------------------------------------------------------------
Ensure Newsletter Delivery

To ensure newsletter delivery, you can add any additional email
addresses you may have to the OTC Journal Member List. Receiving
the OTC Journal Newsletter in multiple locations is the best way of
making sure you don't miss the next investing or trading
opportunity! For web based email addresses, the OTC Journal
recommends @yahoo.com or @aol.com for timely and reliable email
newsletter delivery.

Note: Your email address will be kept strictly confidential, and
will not be shared with any other entity for any purpose at any
time. If you no longer wish to receive the OTC Journal, simply
follow the instructions located at the bottom of every OTC Journal
Newsletter Edition.
--------------------------------------------------------------------



Disclaimer
The OTC Journal Newsletter is an independent electronic
publication committed to providing our readers with factual
information on selected publicly traded companies. All companies
are chosen on the basis of certain financial analysis and other
pertinent criteria with a view toward maximizing the upside
potential for investors while minimizing the downside risk,
whenever possible. Moreover, as described below, this publication
accepts compensation from certain of the companies which it
features. Likewise, this newsletter, which is owned by MarketByte,
LLC also accepts compensation in connection with the dissemination
of information regarding the companies featured. This newsletter
should not, therefore, be regarded as an independent publication.

Go Here to view our compensation on every company we have ever
covered, or visit the following web address:
http://www.otcjournal.com/disclosure/compensation/section/profile/
for our full profiles and
http://www.otcjournal.com/disclosure/compensation/section/alert/
for Trading Alerts.

TGR Group LLC, an affiliate of MarketByte LLC, has been paid a fee
of 300,000 newly issued restricted shares by Biocurex for coverage
of the Company.

All statements and opinions expressed herein are those of the
editors and are subject to change without notice. A profile,
description, or other mention of a company in the newsletter is
neither an offer nor solicitation of an offer to buy or sell any
securities mentioned. While we believe all sources of information
provided by us and contained in our publication to be accurate
and reliable, we cannot and do not guarantee the accuracy of
information we received from third parties.

From time to time MarketByte, LLC sells shares in the open market
it receives as compensation for coverage of client companies.
Since the shares are received as compensation for services as
previously disclosed, and not for investment purposes, the editors
do not view the sale of the shares as contradictory to any advice
delivered in the content. This should be viewed as a conflict of
interest by shareholders or prospective shareholders of the client
companies.

The editor, members of the editor's family, and/or entities with
which they are affiliated aside from MarketBtye LLC itself, are
discouraged by company policy from owning, buying, selling or
otherwise trading stock for their own benefit in the companies who
appear in the publication unless such activities are specifically
disclosed in the newsletter or on the OTC Journal web site. Full
disclosure of position changes is updated on the web site weekly.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE
BEFORE INVESTING IN ANY SECURITIES MENTIONED IN THIS PUBLICATION.
INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE
OF RISK.

We encourage our readers to invest carefully and read the investor
information available at the web sites of the Securities and
Exchange Commission ("SEC") at http://www.sec.gov and/or the
National Association of Securities Dealers ("NASD") at
http://www.finra.org. We also strongly recommend that you read the
SEC advisory to investors concerning Internet Stock Fraud, which
can be found at http://www.sec.gov/consumer/cyberfr.htm. Readers
can review all public filings by companies at the SEC's EDGAR
page. The NASD has published information on how to invest
carefully at its web site. MarketByte LLC's mailing address is
4653 Carmel Mtn Rd Suite 308 #402, San Diego, CA 92130.

The information found in this newsletter is protected by the
copyright laws of the united states and may not be copied, or
reproduced in any way without the expressed, written consent of
the editors of otcjournal.com.
-------------------------------------------------------------------

You can unsubscribe from this list at any time by Clicking Here.
If you are having difficulty removing yourself or wish to change
your address please go to
http://




---
You are currently subscribed to otcjournal as: [e-mail]
To unsubscribe send an email to [e-mail] and make sure to include "Remove" in the subject line.